Table 1 Showing features of death in the temporal association of COVID-19 vaccination
S. no | Study | Adverse effect | Age | Sex | Previous med history | Type of vaccine | Time of onset of symptoms/admission after vaccination | Dose after which symptoms developed or Pnt needed admission | Outcome |
|---|---|---|---|---|---|---|---|---|---|
1 | Tajastra et al. [2] | Acute coronary thrombosis/myocardial infarction | 86 years | M | Previous H/O Ca prostate Status—post surgery and RT On anti-androgen therapy H/O atrial fibrillation | Pfizer BioNTech | After 30 min of injection | 1st dose | Death (3 days after vaccination) |
2 | Blaunfeldt et al. [3] | Thrombocytopenia with acute ischemic stroke and bleeding (B/L adrenal haemorrhage) | 60 years | F | H/o Hashimoto’s thyroiditis +HTN | AZD1222 | After 7 days | 1st dose | Death (on 6th day of admission) |
3 | D’Agostino [4] | Cerebral venous thrombosis and disseminated intravascular coagulation | 54 years | F | H/o Ménière’s disease | AstraZeneca | 12 days | 1st dose | Death (after 5 days of admission) |
4 | Fahmida Bano [5] | Intracerebral haemorrhage and C VST | 53 years | F | H/o fibromyalgia | ChAdOx1 nCoV-19 | 14 days | 1st dose | Death (on 16th day after vaccination) |
5 | Fahmida Bano [5] | CVST and subarachnoid haemorrhage | 55 years | M | NAD | ChAdOx1 nCoV-19 | 10 days | 1st dose | Death (within 24 h of presentation) |
6 | Rela [6] | Autoimmune hepatitis | 62 years | M | H/o DM, past H/o jaundice | Covishield | 16 days | NA | Death (3 weeks after admission) |
7 | Mahmood Nasar [7] | Myocarditis | 70 years | F | H/o multiple sclerosis | Janssen COVID-19 vaccine | 2 days | NA | Death (on 8th day of admission) |
8 | Preethi suresh [8] | VITT and CVST | 27 years | M | NAD | ChAdOx1 nCoV-19 | 48 h | 1st dose | Death (time from admission to death = NA) |
9 | Castelli et al. [9] | CVST and thrombocytopenia | 50 years | M | NAD | AstraZeneca COVID vaccine | 7 days | 1st dose | Death (48 h after admission) |
10 | Tor Halvor [10] | Intracerebral haemorrhage | Thirties | F | NAD | ChAdOx1 nCoV-19 | 7 days | NA | Death (died the following day of admission) |
11 | Massimo Franchinia [11] | CVST | 50 years | M | NAD | AstraZeneca vaccine | 7 days | 1st dose | Death (18 h after intervention) |
12 | Mehta P [12] | CVST and thrombocytopenia | 32 years | M | NAD | Vaxzevria vaccine | 9 days | 1st dose | Death (time from admission to death = NA) |
13 | Mehta p [12] | CVST and thrombocytopenia | 25 years | M | H/o primary sclerosing cholangitis and migraine | Vaxzevria vaccine | 6 days | 1st dose | Death (time from admission to death = NA) |
14 | Gessler [13] | CVT (cerebral sinus and vein thrombosis) | 47 years | F | NAD | ChAdOx1 nCoV-19 | 12 days | 1st dose | Death (39 h after admission) |
15 | Gessler [13] | CVT (cerebral sinus and vein thrombosis) | 50 years | F | NAD | ChAdOx1 nCoV-19 | 7 days | 1st dose | Death (49 h after admission) |
16 | Gessler [13] | CVT (cerebral sinus and vein thrombosis) | 44 years | F | .NAD | Ad26.COV2.S | 10 days | 1st dose | Death (20 h after admission) |
17 | Wiedmann M [14] | VITT and CVT (cerebral venous thrombosis) | 34 years | F | H/o pollen allergy H/o contraceptive vaginal ring | ChAdOx1 nCoV-19 | 7 days | NA | Death (day after admission) |
18 | Wiedmann M [14] | VITT and CVT (cerebral venous thrombosis) | 42 years | F | H/o pollen allergy H/o contraceptive vaginal ring | ChAdOx1 nCoV-19 | 10days | NA | Death (on day 15 after admission) |
19 | Wiedmann M [14] | VITT and CVT (cerebral venous thrombosis) | 37 years | F | H/o pollen allergy H/o oral contraceptive | ChAdOx1 nCoV-19 | 8 days | NA | Death (on day 11 after vaccination) |
20 | Wiedmann M [14] | VITT and CVT (cerebral venous thrombosis) | 54 years | F | H/o HTN. H/o HRT | ChAdOx1 nCoV-19 | 6 days | NA | Death (2 days after surgery/craniotomy) |
21 | Aladdin Y [15] | VITT and DIC | 36 years | F | H/o DM | ChAdOx1 nCoV-19 | 14 days | 1st dose | Death (4 days after admission) |
22 | Choi S [16] | Myocarditis | 22 years | M | H/o HTN | BNT162b2 mRNA | 5 days | 1st dose | Death (few hours after admission) |